Johnsam | Joined since 2021-02-04

Investing Experience -
Risk Profile -





Blog Posts









Total comments
Past 30 days
Past 7 days

User Comments

2022-01-06 16:25 | Report Abuse

Profit also droping previous few quarters


2021-11-22 14:59 | Report Abuse

I think now is institution selling, this counter will need a lot of patience


2021-10-26 11:29 | Report Abuse

With the future earning so bright, i dont think anyone can buy below rm55 after next month especially after all the IB revise their target price


2021-09-02 11:08 | Report Abuse

seem like going into consolidation. Can collect when it's cheaper


2021-08-23 10:15 | Report Abuse

It's ok, even if same growth I am sure dividend will be exceptional


2021-08-20 13:10 | Report Abuse

Based on some of the reports,coming quarters revenue is increasing


2021-08-20 10:33 | Report Abuse

Next quater result may be effected by the ongoing lockdown since they will not be at full capacity but overall industry demand exceed supply in the market. Can keep long term.


2021-08-18 18:05 | Report Abuse

Best quarter result ever


2021-07-27 22:26 | Report Abuse

Bcos of economic slowdown from covid, many chemical companies have slow down their investment to increase their capacity. Now demand coming manufacturing, cables and automotive have exceeded supply and not sufficient to support the demand for this region.

CIMB is putting chemicals counter as overweight and slated to outperform as recovery stock in 2H21.


2021-07-05 20:53 | Report Abuse

100% will fly, substantial shareholders already accumulated since last month


2021-06-25 09:36 | Report Abuse

With so many glove company setting up factories to expand their capacity, the benefactors will be the companies like samchem.


2021-06-10 16:01 | Report Abuse

The fact this counter have Abigail P. Johnson investing in her personal capiticy is a solid credential. Seasoned investor with good track record.


2021-06-09 13:52 | Report Abuse

I think there is profit taking and market will be volatile anticipating whether FMCO will extend or not


2021-06-08 23:36 | Report Abuse

Market will always be volatile that's why only invest in company with good fundamentals.

With solid orders in hand, especially for higher-margin semiconductor and smartphone-related products, Pentamaster Corp Bhd seems to be well-positioned to make a comeback this year. The cash-rich Penang-based company has already begun its financial year 2021 with a 15% jump in sales in the first quarter (Q1), although it was not spared from the sector-wide margin pressure. The company also benefits from the ongoing semiconductor industry “supercycle” as market demand exceeds global supply.


2021-06-04 12:29 | Report Abuse

Source : CGSCIMB
Date 3 July 2021

Pentamaster Corp
We forecast stronger sales contribution from the electro-optical division in
FY21F, driven by a higher conversion rate of prototypes into recurring sales. For
example, the group indicated it received a sizeable order for its new 3Dmagnetometer sensor, which goes into touchscreen applications. Pentamaster’s
order book hovered at the RM230m level as of early-May. In spite of the ongoing
impact of chip shortages and higher raw material cost, the group is upbeat about
stronger sales and earnings recovery from 2Q21F onwards, driven by an
improvement in sales mix towards higher margin solutions in electro-optical and
automotive segments.

We see Pentamaster primed to benefit from the structural shift from the
accelerating adoption of silicon carbide and gallium nitrate power products in
EVs and smartphone fast chargers, given its early-mover advantage and
experience in the power semiconductor market. The group aims to increase its
exposure in the automotive segment from 16% in FY19 to 30% over the next 3-5

The group is investing RM25m to set up a new plant in Batu Kawan, with an
additional 100k sq ft of floor area, to support its factory automation solution (FAS)
and medical device segment expansion from FY22F onwards, given that its
existing plants in Bayan Lepas and Batu Kawan are running at nearly 100% and
75% capacity utilisation, respectively. The group remains upbeat on its medical
device segment, which it projects will contribute 30% to its FY23F revenue.
Overall, we project the group to deliver a 3-year EPS CAGR of 18%. Retain Add,
with a RM5.85 TP, still based on 36x CY22F P/E, +0.5 s.d. above the sector


2021-05-31 22:00 | Report Abuse

Yes, I also cannot trust Kenanga's analyst. They are very good at making char kuey teow.


2021-05-11 13:58 | Report Abuse

We explore Edgenta’s foray into digital healthcare, which begins with the launch of QuickMed (a digital healthcare platform aimed at digitalising healthcare practices in Malaysia). While we have yet to factor in any financial impact from the digital health ventures for the time being, we raise our FY21/22 earnings forecasts by 52.7/65.5% (amid a low base) to account for earnings recovery in Edgenta’s core businesses. After tweaking our SOP-derived valuation methodology and rolling over our valuation year, our TP rises to RM2.53 from RM2.00. Maintain BUY.

Edgenta’s core business currently involves facilities management for the healthcare and infrastructure sectors, which historically accounted for ~45% and ~35% of revenue over the previous 5 years. With Edgenta’s success in adopting technology in their healthcare support services operations, digital healthcare is the logical next step. In this report, we explore Edgenta’s planned digital healthcare ventures going forward.

QuickMed. QuickMed is a platform launched by Edgenta to help healthcare providers digitise their operations and connect to the internet (i.e. their target user base are healthcare providers). QuickMed’s digital solutions include storage of data on cloud, automation of billing, and more. We reckon Edgenta will need to acquire a sizeable user base before these ventures can be monetised effectively.

Potential longer-term business model. We believe QuickMed will be the start of a comprehensive digital healthcare journey. While it is still unclear what monetisation strategies Edgenta will purse, it may come in a few forms, namely: (i) subscription fees from healthcare providers using the QuickMed platform for operations, (ii) selling medical products to users online, (iii) charging fees for value adding services within the platform such as virtual consultations, (iv) charging referrals fees to clinics that patients find via Edgenta’s platforms, (v) selling membership packages to users, (vi) selling wellness packages to users.

Ideal management team. We are enthusiastic about Edgenta’s appointment of Mr. Syahrunizam Samsudin (Managing Director & CEO) in mid-FY20 given his formidable track record in launching and growing digital ventures. Note that during his time at Touch ‘N Go, Mr. Samsudin successfully launched TNG e-wallet as a JV with Ant Financial (affiliate company of Alibaba) which grew to become the largest e wallet in Malaysia.

Forecasts. As Edgenta’s digital healthcare ventures are still in its infancy, we do not factor in any financial impact from the digital health ventures for the time being. However, we raise our FY21/22 earnings forecasts by 52.7/65.5% (amid a low base) to account for earnings recovery from the Infrastructure services division from road maintenance works pushed back into FY21 from Covid-19 disruptions on operations in FY20.

Maintain BUY. We take this opportunity to roll over our valuation year and tweak our SOP valuation methodology (Figure #6). All in all, our TP rises to RM2.53 from RM2.00. In the shorter term, we reckon the share price will be driven by (i) recovery in the infrastructure services earnings from roadworks pushed back from FY20 (ii) projected FY21 healthy dividend yield of 4.8%.

Source: Hong Leong Investment Bank Research - 10 May 2021


2021-05-04 16:09 | Report Abuse

If Opec+ decided to boost production, would this be good for the industry bcos Malaysia will also be boosting their production?


2021-04-27 12:36 | Report Abuse

Another undervalued counter. Will collect now


2021-04-27 12:34 | Report Abuse

Still undervalued at current price


2021-04-26 15:22 | Report Abuse

Hope those that buy last week is making money this week ;)


2021-04-22 20:29 | Report Abuse

Wife: Eh I saw you brought Optimax today. Why? The price is falling wo.

Me: Good to collect now bcos it's cheaper

Wife: What if it's continue to fall?

Me: Then will collect again....


2021-04-08 11:54 | Report Abuse

The counter seems to be picked up by a few investor groups.


2021-04-07 15:24 | Report Abuse

True but he already old maybe he don't want to wait. Since he is selling that we can collect cheap now.


2021-04-07 12:00 | Report Abuse

This show Tan Sri is intelligent and saw opportunity and he still own 50% of the company even after disposal. I am sure he is driven to bring the share higher.


2021-04-06 20:54 | Report Abuse

Every month got millions conversion of preference shares, so this mean there will be endless supply on new shares every month.


2021-04-06 17:15 | Report Abuse

Good opportunity to collect, price is going down is bcos the boss is cashing out some of his share.


2021-03-30 14:21 | Report Abuse

Just be patient, last week Hiap Tek was the top 5 net buy counter from local institutional.Definately a good companies will good fundamentals


2021-03-16 15:59 | Report Abuse

I think there will be some good news from the federal reserve this week and then oil price will be bullish again


2021-03-06 21:55 | Report Abuse

Global shortage on semiconductor chip, get ready for another bull run this year


2021-02-24 11:47 | Report Abuse

Source: TA Securities

Commitment on Special Dividend

Yesterday, Top Glove announced that the group is committed to a special dividend of 20%, in addition to its existing dividend policy of 50% dividend pay-out ratio, for 2QFY21 to 4QFY21. As such, the 70% dividend pay-out ratio on PATAMI will commence from 2QFY21.

To recap, Top Glove declared a first interim dividend of 16.5sen/share in 1QFY21, representing a pay-out ratio of 55.7%. In tandem with this special dividend announcement of 20% for 2QFY21 to 4QFY21, we raise our FY21F dividend pay-out to 66.5% from 55% previously. At current share price, the stock is expected to offer an attractive dividend yield of 18.4% for FY21F.

Klang Factories Fully Ramp Up

In terms of earnings, recall that despite a flattish growth in gloves production in 1QFY21 (i.e., 0.05% QoQ to 17.97bn), Top Glove recorded a PAT of RM2.38bn (+83.9% QoQ) due to higher ASP of 57%. Recall that Top Glove worker’s dormitories in Klang were under the Enhanced Movement Control Order (EMCO) from 17th November 2020 to 14th December 2020, which affected circa-50% of Top Glove’s total production capacity. Due to the timing of the EMCO, we note that the
earnings impact is spread in 1QFY21 and 1QFY22.

According to management, the affected plants have all resumed operation on 20th December 2020 and all the plants are currently operating at full capacity. As such, we expect gloves production in
2QFY21 to be higher QoQ due to the additional capacity. More importantly, ASP for 2QFY21 has increased by circa-30% QoQ.

Given the stronger-than-expected ASP, we now expect Top Glove to record a profit of RM12.5bn for FY21, which is 7.1 times more than FY20 profit of RM1.75bn.


2021-02-24 09:57 | Report Abuse

You never know when it will be the lowest, collected some at 5.48.


2021-02-22 17:39 | Report Abuse

If Top Glove and other institutions are starting to buying now, then I think there will never be a better timing than now. Good entry to buy and keep


2021-02-19 15:24 | Report Abuse

Best time to buy and keep.


2021-02-19 12:39 | Report Abuse

Dialog has a record of 31% yearly compounded growth on their stock since their IPO


2021-02-19 11:08 | Report Abuse

Just this week alone EPF & KWAP has been buying more than 9 million over shares. If you check their previous transactions, they have been buying consistently for many months now. Now EPF hold about 10% and KWAP about 8%. I think oil is gearing for the uptrend.


2021-02-04 18:29 | Report Abuse

Source: Kenanga Research - 3 Feb 2021

YTL’s share price is looking technically interesting following a pullback of 22% from its recent high of RM0.83 in midDecember last year. At the last traded price of RM0.65, the stock is not far away from its March 2020’s trough level of RM0.58 with further downside risk supported by a horizontal line that stretches back to September last year.

As the shares approach the RSI oversold zone, a technical rebound is anticipated when the stock climbs above the oversold threshold going forward.

That being the case, the share price will probably bounce up to reach our resistance targets of RM0.72 (R1; 11% upside potential) and RM0.80 (R2; 23% upside potential).

We have pegged our stop loss price at RM0.59 (which represents 9% downside risk).

Fundamentally speaking, YTL – a conglomerate that is involved in multiple businesses ranging from utilities, cement manufacturing & trading, construction, property investment & development, hotel operations to information technology & ecommerce – is forecasted to register net profit of RM108m in FY June 2021 and RM193m in FY June 2022 based on consensus numbers. This translates to forward PERs of 66x and 37x, respectively.